Back to search

National and Kapodistrian University of Athens

Μελέτη μεταλλαγών στο γονίδιο της καρδιακής τροπονίνης Τ σε Έλληνες ασθενείς που πάσχουν από υπερτροφική μυοκαρδοπάθεια

Abstract

dc:description

Introduction: Hypertrophic cardiomyopathy is an autosomal, dominant familial disease (90%), with sporadic cases happening less than 10%. It is the first cause of sudden cardiac death at ages below 30, with a prevalence of 1/500 in the general population. The involved genes, encoding mostly sarcomeric proteins, are fourteen and the associated mutations are 418. Penetrance is in correlation to the associated pathologic gene. Hypertrophic cardiomyopathy patients, due to cardiac troponin T mutations, have a high risk of sudden cardiac death, even at the absence of any prior symptom. At the initial studies, cardiac troponin T was the third gene with a 15% prevalence, in relation to the disease. Incomplete penetrance, as evidenced electrocardiographically and echocardiographically, is one of the main characteristics of the cardiac troponin T-associated disease. Identification of disease causing mutations at probands will, also, help at the identification of 1st degree relatives, with subclinical or no forms of disease, who are gene carriers. Aim: The aim of the study, is the identification of mutations at the gene of cardiac troponin T in a representative Greek hypertrophic cardiomyopathy population and its penetrance. For this cause one hundred and forty three consecutive, unrelated patients-probands (diagnosis based on clinical and echocardiographic data) were genetically screened. Methods: All 16 exons of the gene were examined. Genetic screening consisted in multiplying each exon or region by the use of polymerase chain reaction (PCR) with specially designed primers for each exon and followed by the use of single strand conformation polymorphism (SSCP), at two, different, temperatures. In cases where there has been a deviation of the single stranded product from the conformation that a normal one would have in a polyacrylamide gel, the use of automated sequencing followed. Where there was sequencing evidence of deviation from the normal sequence, the procedure was repeated with use of fresh blood sample and automated sequencing of the region in question towards both directions (5’-3’ and 3’-5’). In cases of carrier probands’ relatives, genetic screening was carried out by the use of PCR, SSCP and automated sequencing (bidirectional) for the deviated, from normal, single strand conformers of the respective, in question, exon. In each case, deviation from the normal sequence was cross checked against DNA from 100 healthy individuals of Greek origin (200 chromosomes) -general population- so as to identify the presence of mutation or polymorphism. Results: Four (4) probands (three men, one woman) from different families were found with a mutation in the gene of cardiac troponin T. Three mutations were found in two amino acids on the same exon, exon 16. Those mutations were: Arginine-Cysteine, position 278, 2 persons, Arginine-Proline, position 278, 1 person and Arginine-Cysteine, position 286, 1 person. The clinical course and prognosis is different amongst them and each one of them. First degree, and beyond, relatives were informed and participated to the genetic investigation. In total 27 relatives were clinically examined and 18 genetically. Six (6) relatives were found to be gene carriers of the respective mutations, not excibiting, in all cases, the clinical type of the disease. Only 50% of the genetically affected persons fulfilled the typical echocardiographic criterion of left ventricular hypertrophy >13mm. whereas 30% of relatives identified as carriers did not have any clinical or subclinical criterion fulfilled. Those two informations, on their own, underline the need of broad spectrum genetic screening of probands as well as of their relatives. Discussion: The prevalence of cardiac troponin T gene mutations in Greece has been calculated to 2,8%, contrary to the previous international studies, but in accordance to the latest three studies. This study, along with the other three international studies, adds to the knowledge of the low prevalence of cardiac troponin T mutations in HCM proband populations. Correlation of phenotypes with respective genotypes has shown that genetic approach solely, cannot determine the clinical presence, and needs further investigation. Nevertheless, the genetic approach is undoubtfully a very strong “tool” for the identification of subclinical and silent cases of the disease, in the family. Patient evaluation by use of clinical or even subclinical criteria is not adequate for the identification of all hypertrophic cardiomyopathy carriers, whereas the addition of genetic analysis data will bring on a substantial depth in the diagnostics, the therapeutic route and the prevention of the disease.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Miliou, Antigoni
  • Μήλιου, Αντιγόνη

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/26886

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Miliou, Antigoni; Μήλιου, Αντιγόνη. Μελέτη μεταλλαγών στο γονίδιο της καρδιακής τροπονίνης Τ σε Έλληνες ασθενείς που πάσχουν από υπερτροφική μυοκαρδοπάθεια. National and Kapodistrian University of Athens, 2009. http://hdl.handle.net/10442/hedi/26886